The study will test a computerized treatment with subjects ages 13-17 years who are interested in seeking treatment for alcohol and/or cannabis use. Follow-up assessments will be conducted at one- and three-months following treatment.

This study tests a mobile app that aims to reduce alcohol use and risky sexual behavior.

Interested individuals will complete an online screener to see if they are eligible. Eligible participants will complete six mobile sessions over the course of about 45 days.

The first and the last session will be completed via video conference with a member of the research staff. The second through fifth sessions are completed independently on the mobile app. Sessions involve survey questionnaires, clinical interviews, and computerized tasks. Participants will be compensated for completed study sessions.

This study focuses on adolescents who experience both substance use problems and post-traumatic stress disorder (PTSD), which often occur together and can seriously impact mental health, school performance, and relationships if left untreated. The goal is to evaluate a trauma-focused treatment called Concurrent Treatment of PTSD and Substance Use Disorders for Adolescents (COPE-A), which is designed to address both conditions at the same time. Earlier pilot studies showed that COPE-A is safe, feasible, and effective in reducing substance use and PTSD symptoms compared to a supportive counseling approach.

In this larger study, 120 adolescents from across the U.S. will receive treatment through telehealth. Researchers will compare COPE-A to person-centered therapy to see which leads to greater improvements in substance use and PTSD symptoms. The study will also examine effects on depression, HIV risk behaviors, relationships, and overall quality of life, while using brief daily surveys to track changes over time.

Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of organ dysfunction, usually occurring after 20 weeks of pregnancy. It can lead to serious health problems for both the pregnant person and the baby. Although some risk factors for preeclampsia are known, effective strategies to prevent the condition remain limited.

The purpose of this research study is to determine whether vaginal progesterone can help prevent preeclampsia in pregnant individuals. Progesterone is a hormone that is naturally produced during pregnancy and is already used for certain pregnancy-related conditions.

Participants who choose to join the study will be randomly assigned (by chance, like flipping a coin) to receive either vaginal progesterone or no medication. Participants will use the study medication as directed during pregnancy and will continue to receive their routine prenatal care.

Researchers will collect information from prenatal visits, medical records, and delivery outcomes to determine whether progesterone reduces the risk of developing preeclampsia and improves pregnancy outcomes. The information gained from this study may help identify a safe and effective way to prevent preeclampsia and improve the health of pregnant individuals and their babies in future pregnancies.